241 related articles for article (PubMed ID: 27036581)
1. Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2016 Apr; 43(4):1841. PubMed ID: 27036581
[TBL] [Abstract][Full Text] [Related]
2. Risk of developing radiogenic cancer following photon-beam radiotherapy for Graves' orbitopathy.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Med Phys; 2018 Oct; 45(10):4775-4782. PubMed ID: 30105825
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy for non-malignant shoulder syndrome: Is there a risk for radiation-induced carcinogenesis?
Mazonakis M; Lyraraki E; Tzedakis A; Damilakis J
Phys Med; 2017 Nov; 43():73-78. PubMed ID: 29195566
[TBL] [Abstract][Full Text] [Related]
4. Organ-specific radiation-induced cancer risk estimates due to radiotherapy for benign pigmented villonodular synovitis.
Mazonakis M; Tzedakis A; Lyraraki E; Damilakis J
Phys Med Biol; 2016 Sep; 61(17):6400-12. PubMed ID: 27499236
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy for stage I seminoma of the testis: Organ equivalent dose to partially in-field structures and second cancer risk estimates on the basis of a mechanistic, bell-shaped, and plateau model.
Mazonakis M; Varveris C; Lyraraki E; Damilakis J
Med Phys; 2015 Nov; 42(11):6309-16. PubMed ID: 26520723
[TBL] [Abstract][Full Text] [Related]
6. Out-of-field organ doses and associated radiogenic risks from para-aortic radiotherapy for testicular seminoma.
Mazonakis M; Berris T; Varveris C; Lyraraki E; Damilakis J
Med Phys; 2014 May; 41(5):051702. PubMed ID: 24784368
[TBL] [Abstract][Full Text] [Related]
7. Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.
Mazonakis M; Lyraraki E; Damilakis J
Med Phys; 2017 Jul; 44(7):3866-3874. PubMed ID: 28493609
[TBL] [Abstract][Full Text] [Related]
8. Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin's disease.
Kourinou KM; Mazonakis M; Lyraraki E; Papadaki HΑ; Damilakis J
Phys Med; 2019 Jan; 57():100-106. PubMed ID: 30738513
[TBL] [Abstract][Full Text] [Related]
9. Cancer risk estimates from radiation therapy for heterotopic ossification prophylaxis after total hip arthroplasty.
Mazonakis M; Berris T; Lyraraki E; Damilakis J
Med Phys; 2013 Oct; 40(10):101702. PubMed ID: 24089892
[TBL] [Abstract][Full Text] [Related]
10. Peripheral organ doses from radiotherapy for heterotopic ossification of non-hip joints: is there a risk for radiation-induced malignancies?
Berris T; Mazonakis M; Kachris S; Damilakis J
Phys Med; 2014 May; 30(3):309-13. PubMed ID: 24084192
[TBL] [Abstract][Full Text] [Related]
11. A critical evaluation of secondary cancer risk models applied to Monte Carlo dose distributions of 2-dimensional, 3-dimensional conformal and hybrid intensity-modulated radiation therapy for breast cancer.
Joosten A; Bochud F; Moeckli R
Phys Med Biol; 2014 Aug; 59(16):4697-722. PubMed ID: 25082795
[TBL] [Abstract][Full Text] [Related]
12. Monte Carlo study of organ doses and related risk for cancer in Algeria from scattered neutrons in prostate treatment involving 3D-CRT.
Alem-Bezoubiri A; Suleiman SA; Behidj I; Mazrou H; Chami AC
Appl Radiat Isot; 2022 Feb; 180():110065. PubMed ID: 34933226
[TBL] [Abstract][Full Text] [Related]
13. Assessment of radiation-induced second cancer risks in proton therapy and IMRT for organs inside the primary radiation field.
Paganetti H; Athar BS; Moteabbed M; A Adams J; Schneider U; Yock TI
Phys Med Biol; 2012 Oct; 57(19):6047-61. PubMed ID: 22968191
[TBL] [Abstract][Full Text] [Related]
14. SECOND CANCER RISK FROM RADIATION THERAPY FOR COMMON SOLID TUMORS DIAGNOSED IN REPRODUCTIVE-AGED FEMALES.
Mazonakis M; Kachris S; Damilakis J
Radiat Prot Dosimetry; 2018 Dec; 182(2):208-214. PubMed ID: 29608744
[TBL] [Abstract][Full Text] [Related]
15. Screening computed tomography colonography with 256-slice scanning: should patient radiation burden and associated cancer risk constitute a major concern?
Perisinakis K; Seimenis I; Tzedakis A; Papadakis AE; Kourinou KM; Damilakis J
Invest Radiol; 2012 Aug; 47(8):451-6. PubMed ID: 22766908
[TBL] [Abstract][Full Text] [Related]
16. Calculated organ doses using Monte Carlo simulations in a reference male phantom undergoing HDR brachytherapy applied to localized prostate carcinoma.
Candela-Juan C; Perez-Calatayud J; Ballester F; Rivard MJ
Med Phys; 2013 Mar; 40(3):033901. PubMed ID: 23464344
[TBL] [Abstract][Full Text] [Related]
17. Estimation of lifetime attributable risks (LARs) of cancer associated with abdominopelvic radiotherapy treatment planning computed tomography (CT) simulations.
Bagherzadeh S; Jabbari N; Khalkhali HR
Int J Radiat Biol; 2018 May; 94(5):454-461. PubMed ID: 29528791
[TBL] [Abstract][Full Text] [Related]
18. Triple-rule-out computed tomography angiography with 256-slice computed tomography scanners: patient-specific assessment of radiation burden and associated cancer risk.
Perisinakis K; Seimenis I; Tzedakis A; Papadakis AE; Damilakis J
Invest Radiol; 2012 Feb; 47(2):109-15. PubMed ID: 21857528
[TBL] [Abstract][Full Text] [Related]
19. Secondary cancer-incidence risk estimates for external radiotherapy and high-dose-rate brachytherapy in cervical cancer: phantom study.
Lee B; Ahn SH; Kim H; Son J; Sung J; Han Y; Huh SJ; Kim JS; Kim DW; Yoon M
J Appl Clin Med Phys; 2016 Sep; 17(5):124-132. PubMed ID: 27685104
[TBL] [Abstract][Full Text] [Related]
20. Risk of contralateral breast and ipsilateral lung cancer induction from forward-planned IMRT for breast carcinoma.
Mazonakis M; Stratakis J; Lyraraki E; Damilakis J
Phys Med; 2019 Apr; 60():44-49. PubMed ID: 31000085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
